skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Marker evaluation of human breast and bladder cancers

Abstract

We are investigating multiple markers in human breast and bladder cancers. Our aim is to identify markers that are clinically relevant and that contribute to our understanding of the disease process in individual patients. Good markers accurately assess the malignant potential of a cancer in an individual patient. Thus, they help identify those cancers that will recur, and they may be used to predict more accurately time to recurrence, response to treatment, and overall prognosis. Therapy and patient management may then be optimized to the individual patient. Relevant markers reflect the underlying pathobiology of individual tumors. As a tissue undergoes transformation from benign to malignant, the cells lose their differentiated phenotype. As a generalization, the more the cellular phenotype, cellular proliferation and cellular genotype depart from normal, the more advanced is the tumor in its biological evolution and the more likely it is that the patient has a poor prognosis. We use three studies to illustrate our investigation of potential tumor markers. Breast cancers are labeled in vivo with 5-bromodeoxyuridine (BrdUrd) to give a direct measure of the tumor labeling index. Bladder cancers are analyzed immunocytochemically using an antibody against proliferation. Finally, the techniques of molecular genetics are used tomore » detect allelic loss in breast cancers. 6 refs., 3 figs.« less

Authors:
; ; ; ; ; ;  [1]
  1. California Univ., San Francisco, CA (USA)
Publication Date:
Research Org.:
Lawrence Livermore National Lab., CA (USA)
Sponsoring Org.:
DOE/DP
OSTI Identifier:
6316358
Report Number(s):
UCRL-JC-105526; CONF-9007183-3
ON: DE91005242
DOE Contract Number:  
W-7405-ENG-48
Resource Type:
Conference
Resource Relation:
Conference: Clinical applications of flow cytometry and image analysis, Iwate (Japan), 1-3 Jul 1990
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; BIOLOGICAL MARKERS; EVALUATION; BLADDER; NEOPLASMS; MAMMARY GLANDS; EPIDEMIOLOGY; CELL PROLIFERATION; DIAGNOSTIC USES; DISEASES; DNA; IN VIVO; LABELLING; MAN; MOLECULAR BIOLOGY; MONOCLONAL ANTIBODIES; PATHOLOGY; THERAPEUTIC USES; TRACER TECHNIQUES; ANIMALS; ANTIBODIES; BODY; GLANDS; ISOTOPE APPLICATIONS; MAMMALS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PRIMATES; URINARY TRACT; USES; VERTEBRATES; 550901* - Pathology- Tracer Techniques

Citation Formats

Mayall, B H, Carroll, P R, Chen, Ling-Chun, Cohen, M B, Goodson, III, W H, Smith, H S, and Waldman, F M. Marker evaluation of human breast and bladder cancers. United States: N. p., 1990. Web.
Mayall, B H, Carroll, P R, Chen, Ling-Chun, Cohen, M B, Goodson, III, W H, Smith, H S, & Waldman, F M. Marker evaluation of human breast and bladder cancers. United States.
Mayall, B H, Carroll, P R, Chen, Ling-Chun, Cohen, M B, Goodson, III, W H, Smith, H S, and Waldman, F M. 1990. "Marker evaluation of human breast and bladder cancers". United States. https://www.osti.gov/servlets/purl/6316358.
@article{osti_6316358,
title = {Marker evaluation of human breast and bladder cancers},
author = {Mayall, B H and Carroll, P R and Chen, Ling-Chun and Cohen, M B and Goodson, III, W H and Smith, H S and Waldman, F M},
abstractNote = {We are investigating multiple markers in human breast and bladder cancers. Our aim is to identify markers that are clinically relevant and that contribute to our understanding of the disease process in individual patients. Good markers accurately assess the malignant potential of a cancer in an individual patient. Thus, they help identify those cancers that will recur, and they may be used to predict more accurately time to recurrence, response to treatment, and overall prognosis. Therapy and patient management may then be optimized to the individual patient. Relevant markers reflect the underlying pathobiology of individual tumors. As a tissue undergoes transformation from benign to malignant, the cells lose their differentiated phenotype. As a generalization, the more the cellular phenotype, cellular proliferation and cellular genotype depart from normal, the more advanced is the tumor in its biological evolution and the more likely it is that the patient has a poor prognosis. We use three studies to illustrate our investigation of potential tumor markers. Breast cancers are labeled in vivo with 5-bromodeoxyuridine (BrdUrd) to give a direct measure of the tumor labeling index. Bladder cancers are analyzed immunocytochemically using an antibody against proliferation. Finally, the techniques of molecular genetics are used to detect allelic loss in breast cancers. 6 refs., 3 figs.},
doi = {},
url = {https://www.osti.gov/biblio/6316358}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Fri Nov 02 00:00:00 EST 1990},
month = {Fri Nov 02 00:00:00 EST 1990}
}

Conference:
Other availability
Please see Document Availability for additional information on obtaining the full-text document. Library patrons may search WorldCat to identify libraries that hold this conference proceeding.

Save / Share: